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The Neurotrophins and Bone Morphogenic Proteins (BMP) have both 
been implicated in the maintenance of cellular proliferation and apoptosis in the 
developing nervous system. Downstream of both signaling pathways is NRAGE, 
a member of the Melanoma Antigen (MAGE) gene family and, under BMP 
stimulation, activates p38 leading to caspase 3 cleavage. NRAGE possesses a 
highly conserved MAGE Homology Domain (MHD) and a second, less well 
conserved MHD (denoted MHD2) as well as a unique 25 tandem WQXPXX 
hexapeptide repeat region. Binding partners for the MHD and hexapeptide repeat 
regions have been identified but their cellular consequences have not been 
defined. Therefore, a structure-function analysis of NRAGE was performed to 
identify whether it is the MHD or the repeat region that tranduces the apoptotic 
signal. Nine NRAGE deletion mutants were built to isolate the identified regions 
and expressed in PI9 cells, a neural development model system. Through 
Annexin V staining, it was found that the MHD is essential for apoptotic function 
and the hexapeptide repeat region does decrease the degree of cellular death. The 
MHD region also induces p38 activation and caspase 3 cleavage, as well as 
apoptosis. Overall, these studies ascribe yet another function to the highly 
conserved MHD and give further insight into the mechanisms governing neural 
progenitor cell apoptosis. 
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Chapter 1 
INTRODUCTION 
Apoptosis is an Active and Selective Mechanism in Neural Development 
The development of the mammalian nervous system begins in the early 
stages of embryogenesis and is not complete until the organism reaches 
adulthood. The brain and spinal cord are derived from the neural tube, a single 
layer of cells generated from the neuroepithelium. The cerebral cortex is 
generated through a series of events through which proliferation and 
diversification of a neural stem cell begins with its birth and its terminal function 
is defined by its birth date and the environment in which it receives its cues' 
(reviewed in 2). There is a significant overproduction of neurons and, as a result, 
the brain is developed through a finely balanced mechanism of cell proliferation 
and apoptosis, or programmed cell death '-'. Too little proliferation or too much 
apoptosis in development can result in mental retardation and dementia later in 
life (reviewed in 6 ) .  Conversely, too much proliferation or too little apoptosis can 
result in neuroblastomas and astrogliomas, central nervous system cancers with 
very poor prognosis. Thus, an extremely significant method of both pruning the 
developing brain and maintaining tissue homeostasis is apoptosis. 
Apoptosis is often the cells' response to genetic instability, working on the 
premise that a cell is better dead than damaged (reviewed in 7). However, 
apoptosis or programmed cell death, is also a normal developmental mechanism 
to control cell number and remodel tissues 9. The molecules involved in apoptosis 
are evolutionarily conserved with a substantial expansion of gene families as the 
phylogenic tree diversifies 7. Caspases (cystienyl, =artate specific prote-) are 
major executioners of the apoptotic process and are subdivided into initiator and 
executioner molecules, both of which require dimerization and proteolytic 
cleavage to initiate downstream effects. Upon internally mediated mitochondria1 
permeabilization, cytochrome C is released and forms the apoptosome, an 
aggregate of APAF- 1 (apoptosis protease activating factor), ATP, and cytochrome 
c (the intrinsic apoptotic pathway, reviewed in 7). Herein the pro- initiator 
caspases are cleaved and these molecules can subsequently initiate the cleavage of 
executioner caspases (such as 3 and 7) which leads to cell death (figure 1). The 
extrinsic pathway works ultimately in a similar mechanism but is initiated through 
cell external cues. Upon appropriate ligand binding, the extrinsic pathway can 
utilize molecules such as SMACIDiablo (Second Mitochondria1 Activator of 
CaspaseIDirect IAP binding protein with low PI) to release the inhibition that an 
Inhibitor of Apoptosis (IAP, XIAP being the prototypic molecule) family member 
has on caspase cleavage (Reviewed in 7). 


Labeling of apoptotic cells by virtue of their fragmented DNA showed that 
apoptosis is substantial in the developing mouse cortex, beginning at around E 
(embryonic day) 12, peaking at E l 4  and decreasing to nearly negligible levels in 
the adult 4. The majority of apoptotic cells in the developing brain are in the 
proliferative zones of the developing cortex such as the primoridal plexiform 
layer and the ventricular zone 4. 
Up to 70% of cells are dying in the proliferative zones at E l 4  and this 
steadily decreased until about 1% of cells are actively apoptosing in the adult '. 
Furthermore, a large proportion of apoptotic cells are actively synthesizing DNA 
within an hour prior to death, as shown by BrdU staining ? This suggests that 
cells are active in the cell cycle as they are apoptosing, indicating that cell cycle 
activity is a significant event in initiating apoptosis. Although the dogma has 
been that post-mitotic neurons can not re-enter the cell cycle, current theories 
suggest that post-mitotic neurons can re-enter the cell cycle but this triggers 
apoptosis lo. Several cell cycle molecules such as cyclin D-CKD and RbtE2F are 
upregulated in cortical neurons and cell culture lines exposed to apoptosis 
11 inducing factors such as UV-irradiation . Furthermore, Gl/S checkpoint 
molecules, such as CDK416, Rb, p107 and p130, have all been shown to be 
critical for post-mitotic neuron survival, thus expression in post-mitotic neurons is 
12 often observed in cells undergoing apoptosis signaling events (reviewed in ). 
Overall, this demonstrates that post-mitotic neurons have a fail-safe mechanism; 
for when the cell cycle exit checkpoints are breached, apoptosis cascades are soon 
triggered, preventing the cell from re-entering the cell cycle and possibly damage 
the cell and organ as a whole. 
Identification of NRAGE and Regulation of NRAGE Expression and Activity 
Using the p751cD (Intracellular Domain) as bait, a single clone from an E l 3  
(embryonic day 13) mouse library was isolated and named NRAGE for 
Neurotropin Receptor-Interacting MAGE Homolog 13. In parallel, two similar 
proteins, MAGE-Dl l4 and Dlxin-1 l5 were cloned from human and mouse yeast- 
two hybrid screens respectively. These were subsequently found to be orthologs 
with 87% identity to the human MAGE-Dl and with 97% identity in the c- 
terminal 3 15 amino acids, including the hexapeptide repeat region 1 3 .  NRAGE is 
encoded on the X-chromosome and contains a MAGE homology domain (MHD) 
as well as a 25 tandem WQXPXX hexapeptide repeat region (unique to any 
mammalian genome), characteristics which classify it as a MAGE-D family 
member l6  (figure 2). The MHD region is extremely well conserved in the 
MAGE-D subfamily and is partitioned on multiple exons, a unique feature of the 
MAGE-D genes and suggestive of these genes being evolutionarily the earliest 
MAGE genes 16. There is also a second, less well conserved MHD region 
(denoted MHD2) which is only found in the MAGE-D family, E l  and L2 genes. 
NRAGE is a 775 amino acid protein with a molecular weight of about 87 kDa 13. 
NRAGE co-immunoprecipitates with p75NTR when both proteins are 
endogenously- or over-expressed. NRAGE co-immunoprecipitates when the p75 
ICD is aberrantly expressed, but NRAGE does not co-immunoprecipitate with the 
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p75NTR C-terminal death domain on its own signifying that the death domain is 
not responsible for NRAGE interaction l 3  . 
mRNA expression of NRAGE is ubiquitous, from the early embryo and 
extra embryonic tissues into adulthood. However, protein expression is highly 
regulated both temporally and spatially and is found predominantly in the 
developing brain 17. Further inspection with antibodies against markers of 
neuronal differentiation found that NRAGE was co-expressed with cells reactive 
to neural and glial progenitor populations, as marked by NF-68 (neurofilament- 
68) and GFAP (Glial Fibrillary Acidic Protein) respectively, but did not co- 
localize with the late-neural marker MAP2ah (Microtubule Associated Protein 
2a/b). This demonstrates that NRAGE is originally expressed throughout the 
neuroepithelium while later in development, expression is found in committed but 
undifferentiated populations of cycling progenitors and is not expressed in post- 
mitotic neurons susceptible to changes in neurotrophin expression 17. This 
temporally regulated expression is significant as neurotrophin-dependent survival 
of neurons begins at around E l 6  and continues into adulthood, suggesting that 
NRAGE expression can be an apoptosis effector of the neurotrophin pathway 13. 
Notably, NRAGE was also expressed throughout the cerebral cortex where 
p75NTR expression was completely absent l8  suggesting that NRAGE has 
functions outside of p75NTR mediated signaling (further described below). 
To clarify the downstream effects of NRAGE induced apoptosis, a series 
of biochemical assays were performed to determine how NRAGE confers its 
apoptotic effect. Upon NRAGE over-expression there are increased levels of 
activated effector caspases 3 and 7 19. Using a tetracycline-inducible NRAGE 
adenovirus, cell death was rescued when broad spectrum caspase inhibitors BAF 
or zFAD-fmk were added, collectively signifying NRAGE mediates cell death 
19 through caspase activation . Release of cytochrome c from the mitochondria, 
brought on by active caspase 9 and APAF-1 complexing with cytochrome c, is a 
key step in the apoptotic process20921. In NRAGE-adenovirus infected cells, high 
levels of cytochrome c were detected in the cytoplasmic fraction indicating that 
NRAGE over-expression can contribute in the release of cytochrome c from the 
mitochondria. However this was not the result of activated caspase 9 because 
cells treated with the caspase inhibitor showed an accumulation of cytochrome c 
in the cytosolic fraction, indicating that cytochrome c is released from the 
mitochondria in the absence of caspase activation 19. This means that 
mitochondria1 membrane depolarization and the release of cytochrome c under the 
regulation of NRAGE are independent of the activation of caspase 9 and is not 
required for the apoptosome to form19. 
NRAGE's Role in Cell Proliferation and Differentiation 
There is increasing evidence that misregulation of cell cycle molecules 
and breach of cell cycle checkpoints is one possible mechanism for neural 
22-25 progenitor and post-mitotic neuron- induced programmed cell death . 
Through BrdU incorporation assays, it was found that NRAGE over-expression 
attenuates cell cycle progression in human endothelial kidney 293 cells 13, 26 
NRAGE over-expression induced p53 expression as early as 24 hours post 
transfection, and also induces activation of p21w"" and p27kip' within 24 hours, 
maximally at 72 hours, indicating growth arrest at the G1-S transition within 72 
22, 26 hours of NRAGE over-expression . Apoptosis, as measured by Annexin V 
staining was greatly attenuated when p53 was knocked down in P19 cells treated 
with either Retinoic Acid (RA) or Bone Morphogenic Protein (BMP) suggesting 
that p53 is a downstream participant of NRAGE-mediated apoptosis through 
BMP activation 22. Using p53-null mouse embryonic fibroblasts, it was shown 
that after 2 days of NRAGE over-expression, there is no change in cell cycle 
kinetics suggesting that p53 is downstream of NRAGE-induced activity 2f Taken 
together, these experiments demonstrate that NRAGE can act upon the cell cycle 
by influencing the phosphorylation status of p53 which in turn mediates 
ciplwaf downstream p21 and p27kip' activities on the cell cycle 22326. 
Through Western blot analysis it was also seen that the level of 
phosphorylated p38 was increased within the first 48 hours of NRAGE expression 
then decreased precipitously at 72 hours 22. AS p38 is a downstream mediator of 
TAKl -TAB 1 (TAKl: TGFP-Activated Snase ,  TAB 1 : U K l  binding protein) 
induced BMP signaling, this implies that NRAGE is an indirect mediator of p38 
activation. NRAGE over-expressing cells at 24 hours showed an increase in the 
G2-M phase of the cycle, and at 48 hours most were either at G1 or in S phase 
which was maintained at 72 hours, signifying an increase in cell cycle kinetics 22. 
However, when a pharmaceutical p38 inhibitor was used, TAK dominant negative 
construct overexpressed, or TAK morpholino expressed to knockdown 
expression, NRAGE over expressing cells incurred rapid cell cycle arrest at GI ,  
and this was sustained over the 72 hour period. Furthermore, a dominant negative 
SMAD5 was co-transfected with NRAGE and as predicted, there was a cell cycle 
arrest at G2, signifying a bipotential role of BMP-signaling through NRAGE 22. 
Permanent withdrawal from the cell cycle is requisite for differentiation of 
cells to mature phenotypes. As NRAGE was shown to influence the cell cycle 
and over-expression can induce apoptosis, it is likely that NRAGE plays a role in 
differentiation. As NRAGE over-expression is often lethal to cells, a morpholino 
was utilized to knockdown NRAGE expression in P19 cells which were treated 
with retinoic acid to induce neuronal differentiation. Cells treated with the 
NRAGE morpholino showed a drastic reduction in the number of post-mitotic 
neurons as demonstrated by MAP2ah staining while the number of GFAP+ glial 
cells remained constant. By contrast, the number of Nestin positive cells was 
increased in NRAGE morpholino treated cells, evidence of the cells' inability to 
terminally exit the cell cycle and differentiate into neurons 22. Semi-quantitative 
RT-PCR showed that it was not the inability of the cells to produce pro-neural 
genes such as Mash1 in NRAGE knockdown cells, but rather there was a 
maintenance of stem-like gene expression such as Oct4/5 and neural 
differentiation antagonists Hesl and Hes5 22. Overall, these data suggest that 
NRAGE is required for the terminal exit of the cell cycle in neural progenitor 
cells and a loss of cell cycle control can lead to NRAGE induced apoptosis 
through a BMP dependent pathway which includes the downstream activation of 
p38 22. 
Necdin 
37-34 Necdin is a type I1 MAGE gene - and is the closest homolog to NRAGE 35. 
Maternal Necdin is silenced, and loss of paternal Necdin, most often through 
abnormal imprinting, is associated with Prader-Willi syndrome, a neuro- 
behavioural disorder characterized by respiratory distress and hypotonia in 
neonates, and hyperphagia causing severe obesity, hypogonadism and behavioral 
problems in childhood 36. Over-expression of Necdin strongly suppresses cellular 
proliferation by blocking entry into the cell cycle and can associate with cell cycle 
proteins p53 and E2F1 to inhibit their activity, inducing cell cycle arrest in 
progenitor cells. These interactions occur at Necdin's MAGE Homology Domain 
and it has further been shown that Necdin can form homodimers through its 
MHD. Because of these observations, the potential for interaction of Necdin and 
NRAGE through their respective MHD to induce cell cycle arrest and/or 
differentiation was investigated 'O. Full length NRAGE and deletion mutants 
which include the MHD were constructed and upon over-expression were show to 
immunoprecipitate with ~ e c d i n "  (figure 3). NRAGE binds to Necdin at the 
MHD and NRAGE can also interact with MsxlIMsx2 at the repeat region, 
resulting in a trinary complex 'O. Both Msxl and Msx2 co-immunoprecipitate 
with Necdin both in the presence and absence of NRAGE but could not associate 
with Necdin with a mutation that can not bind to NRAGE. This suggests that 
Msxl or Msx2 can bind to Necdin only when Necdin is able to bind to NRAGE 
(likely a form of conformational change) 'O. 
HAP: requires RING domain to interact with NRAGE (unknown NRAGE region required 67) 
p75NTR:rquires juxtamembrane region to interact with NRAGE (unknman NRAGE region required) 
UNCSHI :requres h - 5  and PESTrcgion to interact with NRAGE MHD 
Praja 1 :requires RING domain t~ interact with NRAGE MHD 
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Figure 3: Map of NRAGE with Corresponding Interactions with Adaptor Proteins. 
Representative map of mouse NRAGE identifying the regions required for interactions with 
various proteins (identified as bracketed regions), Shown are the identified domains with the 
corresponding amino acid counts. References: Prion protein9', DIXS '~ ,  M ~ X I / M S X ~ " ,  BRCAI ", 
~ecdin",  Prajal/Neurodap- 19', UNCSHI'~,  XIAP~' (MHD: MACE Homology Domain). 
To determine how this interaction affects cells, C2C12 muscle cells were 
utilized because Msx2 can repress transcriptional regulation of myogenic 
differentiation genes in these cells. NRAGE over-expression released the 
transcriptional repression effects of Msx2 potentially through a competitive 
binding me~hanism'~. Necdin over-expression alone increased the expression 
muscle differentiation genes MHC (myosin heavy chain) and MyoD each by a 
factor of three. However, when Necdin and NRAGE were both over expressed, 
MH D:'Nerdin domain MHD2 domain 
\ -- --v----.J 
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MHC expression increased nine-fold and MyoD expression increased five-fold. 
C2C12 cells naturally express NRAGE, so Necdin may augment the effects of 
NRAGE in sequestering of Msx2, thereby releasing inhibition of the 
differentiation of C2C 12 cells ". However, a caveat to this data is that C2C 12 
cells do not express Necdin at detectable levels, and there is no normal tissue that 
has endogenously high levels of Msx and Necdin together, signifying that these 
results may be strictly interpreted in vitro. Having said that, Necdin and NRAGE 
may interact in other tissues as both are expressed in P19 cells, brain and skeletal 
muscle. It may be that Necdin's influence on the cell cycle can be monitored by 
NRAGE and that any inability of Necdin to prevent the cell from cycling may 
trigger NRAGE to induce differentiation. 
NRAGE is a Kev Mediator of the Neurotrophic Theorv 
The neurotrophic theory outlines the role of target-derived neurotrophic 
factors in regulation of cell survival during neural development ' (reviewed in 37). 
As a direct result, the theory defines the role of apoptosis in neural development 
as a necessary mitigating factor in the control of cell number and overall tissue 
architecture 9. Neurotrophic factors are the survival signals produced by the 
target tissue (outlined below), and through their production, the target tissue 
regulates the neuronal input it receives. This regulation can be accomplished in 
three ways: regulation of production of neurotrophins; the regulation of their 
secretion; or the limited uptake by pre-synaptic terminals (reviewed in 7). 
The neurotrophins are a family of growth factors which include Nerve 
Growth Factor (NGF), Brain Derived Neurotrophic Factor (BDNF), Neurotrophin 
415 (NT415) and Neurotrophin-3 (NT3). Apart from regulating survial, these 
growth factors also regulate dendritic and axonal growth as well as synaptic 
activity The neurotrophins also preferentially bind to pairs of growth factor 
receptors termed Trk (Tyrosine Receptor Kinases) and p75NTR (Neurotrophin 
Receptor). NGF preferentially binds to TrkA, BDNF and NT415 to TrkB and 
NT3 to TrkC, and each of these can bind to the p75NTR as shown by co- 
40, 41 irnrnunoprecipitation when the proteins are over expressed . The Trks have 
no sequence similarity to p75NTR and activate distinct neurotrophin-dependent 
pathways but p75NTR does cooperate to increase the binding affinity of the 
respective neurotropins to their receptors 42 and enhance NGF-mediated TrkA 
42-44 activation . 
p75NTR has a significant role in cell death in a wide range of biological 
settings within and beyond the nervous system. In vivo studies have shown that 
over-expression of the intracellular domain results in widespread neuronal 
45 46 apoptosis in the developing central and peripheral nervous systems , . 
Accordingly, a lack of NGF, disruption of the association of NGF to p75NTR in 
cells, or mice lacking full length p75NTR (i.e. dominant negative receptor) results 
46-50 in decreased apoptosis in the retina and spinal cord . Furthermore, the Janus 
N-terminal kinase (JNK) pathway is up-regulated upon initiation of NGF 
dependent apoptosis, and pharmaceutical inhibition of JNK signaling 51,52 or 
dominant-negative " expression of JNK attenuates NGF-dependent cell death. 
The first investigation of NRAGE as a mediator of NGF-dependent death 
was conducted. in MAH cells, an immortalized sympathoadrenal cell line. These 
cells naturally lack p75NTR and TrkA receptors and do not apopotose when 
NTR 44 stimulated with NGF even in the presence of exogenous expression of p75 . 
Furthermore when NRAGE is over expressed, the cells show no increase in 
apoptosis when stimulated with NGF, demonstrating that NRAGE was not 
sufficient to mediate cell death in the absence of downstream receptor-mediated 
13 NGF activation . However, when MAH cells stably expressing p75NTR were 
transfected with NRAGE, there was a significant reduction of cell survival when 
treated with NGF. Treatment with NGF also showed an increase of NRAGE at 
the membrane suggesting that recruitment of NRAGE to the membrane- 
JSM 
Figure 4: p7sNTR-~ediated Avovtotic 
Signaline Cascade. p7sNTR mediates 
the apoptotic signaling cascade through 
NRAGE. Upon ligand activation, 
NRAGE signals through the MAP 
kinase pathway to phosphorylate JNK. 
Upon JNK activation there is a release of 
the apoptotic inhibitory molecules (such 
as BH3 molecules Bim, Bad, and 
SMACtDiablo) which in turn, facilitates 
cytochrome c release and caspase 
activation, ultimately resulting in 
apoptosis (adapted from Barker, PA, 
2004" j 
associated p75NTR is required for the initiation of the apoptotic cascade. This 
effect was specific to NGF, as neither BDNF nor NT3 induced cell death. 
Overall, this shows that NRAGE expression is requisite to NGF-mediated cell 
13 death through the p75NTR receptor . Conversely, when MAH cells were 
exogenously expressing p75NTR, TrkA and NRAGE, and treated with NGF, there 
was a rescue of cell survival, possibly through survival mechanisms mediated by 
NGF 1 3 .  Induced NRAGE expression activated the JNK pathway and activated 
caspases 3, 7, and 9, as well as showing cytosolic accumulation of cytochrome c. 
Blockage of the pathway at JNK and c-Jun reversed the effects on caspase 
cleavage and rescued apoptosis 1 9 .  Overall, these results demonstrate NRAGE is 
a mediator of p75NTR signaling through JNK resulting in caspase-mediated cell 
death (figure 4). 
UNCSH1 
UNC5Hl is a membrane associated receptor that is the closest family 
member to p75 NTR 54 and is known to be involved in axon guidance and apoptosis. 
Williams et a1 " have shown that UNC5Hl can also associate with NRAGE. 
Through mutational analysis it was found that the C-terminal tail of NRAGE, 
including the MAGE domain is necessary to interact with UNC5Hl while the ZU- 
5 domain of UNC5Hl is required to interact with NRAGE specifically (figure 3). 
This interaction occurs predominantly at the cell membrane ". TO understand the 
functional consequences of these interactions, PC12 cells were used to determine 
how these two proteins mediate neural differentiation. Native PC12 cells express 
NRAGE at high levels but expression is significantly down-regulated upon 
differentiation, coincident with the inability of LTNCSH 1 to co-immunoprecipitate 
with NRAGE in differentiated PC 12 cells. Over-expression of UNCSH 1 in native 
PC12 cells induced massive apoptosis but the percentage of apoptotic cells 
diminished to neglible levels in differentiated cells. NRAGE transfection resulted 
in a mild increase in apoptosis in differentiated PC12 cells, partially rescued by 
over-expression of both constructs. Surprisingly, the over-expression of NRAGE 
in differentiated PC12 cells caused the cells to retract their processes, in the 
presence or absence of LTNCSHI suggesting multiple mechanisms of NRAGE 
activity in the development of neural architecture ". 
NRAGE's involvement in BMP-mediated Cell Death 
Several reports have demonstrated that Bone Morphogenic Proteins 
7'3 56.57 (BMPs) and their receptors are expressed in the developing brain --.- . The 
temporal and spatial regulation of BMP signaling is highly regulated, as was 
shown in two elegant experiments using chick embryos and cortical progenitors 
56.57 
. In chick embryos, high levels of BMP4 expression in even numbered 
rhombomeres induces the expression of Msx2 in odd-numbered rhombomeres and 
increases the rate of apoptosis of neural crest cells 56. In E l3  rat cortical cultures, 
BMP at IOnglmL shows substantial apoptosis. However, BMP treatment of El6  
rat cortical cultures results in an increase in neuronal differentiation at the expense 
of glial differentiation while not altering the percentage of undifferentiated cells 
". Delaying the addition of BMP4 to E l6  cortical cells by three to four days 
produces an increase in astrocytic differentiation, confirming the responses of the 
cell to BMP stimulation are time sensitive 57. This suggests that at early stages of 
neural development, BMP signaling is involved in patterning as well as apoptosis 
and pruning of the neural precursor population, while at later stages it is involved 
in pro-neural differentiation. Noggin, the BMP receptor antagonist, added to E l 6  
cortical progenitors results in an increase of oligodendrocytes at the expense of 
neurons, suggesting that BMP influence cortical cells by inhibiting 
oligodendrocyte differentiation and promoting neuronal differentiation. 
Importantly, BMP2 protein is abundant in the E l 6  cortex and in the neonate, and 
is present in the cortical plate and ependymallsubependymal region but absent in 
the white matter and corpus collosum. These reports illustrate that BMPs are 
essential in the developing brain to regulate brain cellular architecture through 
patterning effects of cellular differentiation and apoptosis ''. 
NRAGE protein expression increases significantly upon treatment with 
RA and BMP4, a rise accompanied by an increase in activated caspase 3 22. 
Through the use of morpholinos to knock down NRAGE expression, the loss of 
NRAGE rescues the apoptotic effects of RA and BMP4 addition. Concurrently, 
the NRAGE knockdown stayed the increase in caspase activation, signifying that 
NRAGE is required for apoptosis in P19 and neural explants. NRAGE associated 
with all three BMP receptors, weakly with the SMAD proteins but very strongly 
with TAK1, TAB1 and XIAP, members of the non-canonical BMP pathway 
known to activate downstream p38 but only in the presence of BMP4. The 
phosphorylation status of p38 was increased in the presence of BMP4-stimulated 
NRAGE, correlative with the level of TAKl, signifying that p38 activation is 
downstream of NRAGE and TAKl and ultimately, BMP4 activation of receptor. 
Abrogation of p38 activity through the use of the chemical inhibitor SB203580 
resulted in a decrease in apoptosis (as seen by flow cytometry). This was also 
confirmed though the use of a morpholino diminishing TAKl levels and a 
SMAD5 dominant negative construct, demonstrating that both pathways are 
required for NRAGE-mediated BMP-induced apoptosis through the 
SMAD 
Figure 5: Canonical and Non-Canonical BMP Signaling. Schematic diagram of BMP 
signaling through the canonical SMAD adaptor proteins and the non-canonical pathway 
mediated by NRAGE. NRAGE is hypothesized to form a complex with XIAP, TAKl and 
TAB 1 to initiate p38 activation and downstream apoptotic responses (diagram courtesy J. 
Verdi) 
phosphorylation of p38 ". 
Classical BMP signaling involves the members of the SMAD family of 
co-factors, which are shared with the TGFP super family, of which the BMPs are 
a subfamily. The canonical pathway involves SMAD 1, 5 or 8 complexing with 
SMAD4, the co-factor, and the heterodimeric complex translocating to the 
nucleus where it activates transcription 58 ,  59. SMADs 6 and 7 are inhibitors of 
the complex and generally are signaled through a separate but parallel mechanism 
to inhibit transcription. However, a second signaling pathway has been described 
which utilizes XIAP as the bridge between TAB1 and TAKl and elicits 
downstream events in the JNK, NLK and MAPK pathways 60. TAKl is an 
activator of TAB1, a member of the MAPKKK family and is stimulated upon 
TGFPl or BMP4 activation " and upon over-expression can induce ventral 
mesoderm formation (see figure 5). 
XIAP 
NRAGE was also identified through a yeast two-hybrid screen as a 
binding partner for XIAP (X-linked Inhibitor of Apoptosis) 62. AS a member of 
the Inhibitor of Apoptosis (IAP) family, XIAP has an amino-terminal cystiene 
rich baculovirus IAP domain (BIR) and a RING zinc finger motif. XIAP was 
originally characterized as a protein that links the BMP receptors to downstream 
TAKl and TAB1 and it had previously been shown that XIAP can bind to the 
BMP receptors through its RING domain and to TAB1 via its BIR domain ". 
XIAP can also interact with the nuclear protein XAF1, and SmacIDIABLO can 
sequester XIAP to prevent its anti-apoptotic activity ""'. Furthermore it has also 
been implicated in JNK and NF-KB signaling 60,66. NRAGE interacts with the 
RING domain and not the BIR domain of XIAP (figure 3). 32D cells are a 
promyeloid leukemic cell line, and a well established model for studying 
apoptosis by growth factor withdrawal as they undergo high rates of apoptosis 
upon Interleukin 3 (IL-3) withdrawal. When NRAGE is over-expressed, there is a 
significant increase in the number of apoptotic cells upon growth factor 
withdrawal, seen at a faster rate than with IL-3 withdrawal alone. Furthermore, 
the increase in apoptosis upon NRAGE over-expression is co-committant with an 
interaction of NRAGE with XIAP. Bcl-2 over-expression can rescue growth 
factor removal induced apoptosis in 32D cells, however, upon NRAGE 
overexposure, the effects of Bc12 over-expression are completely abolished and 
cells undergo a similar rate of apoptosis upon IL-3 withdrawal 67. This signifies 
that NRAGE and XIAP cooperate to induce apoptosis in 32D cells. However, 
the region to which XIAP interacts with NRAGE is not known, nor is it known 
whether this interaction is required for apoptosis during neural development. 
Understanding the region of NRAGE that is required for apoptosis, whether it is 
through a mechanism with XIAP, upstream or downstream molecules remains to 
be elucidated. 
MsxIDlx 
The mouse transcript of NRAGE was discovered through an interaction with 
Dlx5, a member of the Dlx family of homeodomain proteins that are widely 
expressed in the developing forebrain, limbs and branchial arches during 
embryonic development 6"69 and is specifically expressed in developing bone and 
induced in the process of bone fracture healing 68,70-73 . In this study NRAGE was 
identified in a yeast-two-hybrid screen and the 25 hexapeptide repeat of 
WQXPXX of was identified as the region most likely to bind with the N-terminal 
domain of D1x5 as this sequence was overlapping in all the clones identified l S  
(figure 3). Full length NRAGE and deletion mutants encoding the WQXPXX 
region could immunoprecipitate with D1x5 as well as D1x7 and Msx2, other 
members of the DlxIMsx homeodomain protein family 'O. Both D1x5 and Msx2 
are induced by BMP-signaling and Msx proteins are involved in neural 
23, 75 development 74 and in the BMP-mediated cell death pathway . Msxl and 
Msx2 have been shown to be downstream regulators of BMP-mediated apoptosis, 
and in P19 cells Msx2 over-expression can rapidly induce apoptosis only when 
cells are in monolayer 75. Importantly, BMP treatment of Msx2-expressing P19 
cells did not augment apoptosis, signifying that over-expression was enough to 
induce apoptosis but addition of BMP to native P19 cells did result in an increase 
in Msx2 transcript 7', possibly because the BMP pathway was saturated by Msx2 
over-expression. However, unpublished data by Masuda et a1 ", indicate that 
BNIP treatment of three cell lines including P19 did not alter the expression level 
of NRAGE. Overall, these results indicate that BMP-mediated apoptosis through 
Msx2 could be mediated by NRAGE. In situ data demonstrates that this may 
occur in the bone or developing limb as well as in the brain, as was originally 
described. 
A Structure-Function Analysis of NRAGE is Warranted to Identify the 
Functional Domains of the Protein 
Published literature demonstrates that NRAGE can bind to a number of 
varied binding partners and is associated with apoptosis in a number of 
developmental and cellular contexts (summarized in figure 3). The majority of 
these studies were borne of a yeast two-hybrid screen, which used a specific bait 
to isolate NRAGE. The regions of NRAGE involved in the binding of these 
proteins have not fully been characterized, especially in the case of XIAP and 
p75NTR. Moreover the functional significance of these interactions have not been 
characterized with respect to their actions within and upon the cell. Surprisingly, 
the known interactors of NRAGE are also diverse in their own functions and these 
studies indicate that NRAGE has more functions than apoptosis alone. Thus, a 
structure-function investigation of the domains of NRAGE is warranted to 
identify how NRAGE can interact and carry out its functions. Unlike the other 
MAGE family members, MAGE-D genes have unique repeat regions as well as a 
second less well-conserved MAGE homology domain. NRAGE has been shown 
to interact with many molecules within apoptotic pathways but has since been 
shown to be important in other cellular mechanisms as well. The repeat region of 
NRAGE can associate with D1x5 and MsxlIMsx2, proteins involved in BMP 
mediated apoptosis. The MHD of NRAGE can interact with Necdin and 
UNC5H1, both of which are involved in neural development however the 
functional significance of these interactions remains elusive. XIAP, a member of 
non-canonical BMP signaling pathway has also been shown to interact with 
NRAGE, but like p75NTR, the region responsible for these interactions has not 
been found (see figure 3 for a summary). Given the duality of NRAGE as a 
regulator of the mitotic index and apoptosis; we sought to ascribe specific 
NRAGE domains to these functions. We generated a series of deletion constructs 
that target each domain, similar to the classical structure-function studies of Shc 
76, TrkA 77, and NADE 78. TO test these constructs in a neural differentiation 
paradigm, we utilized the P19 cell system to assess the roles of the individual 
regions in apoptosis. Both the WQXPXX region and MHD regions are known to 
interact with several proteins, thus our hypothesis is that these regions are 
essential to NRAGE functions. Furthermore it is hypothesized that this region is 
the region responsible for the downstream p38 activation and caspase cleavage 
previously described as essential to NRAGE-mediated apoptosis upon BMP 
stimulation. It was found that the repeat region is important but the MHD is 
essential for NRAGE mediated apoptosis. These actions are mediated by p38 and 
through which apoptosis is initiated through caspase 3 cleavage. Overall, these 
studies will help to clarify the role of the identified regions of NRAGE and 
ascribe functions to the regions and potentially to their binding partners as well. 
Chapter 2 
MATERIALS AND METHODS 
NKAGE Deletion Clones 
An adult ICR mouse brain was dissected free of meninges, washed twice 
with sterile PBS, minced, homogenized and RNA isolated using the Trizol 
reagent as per the manufacturer's protocol. cDNA was reverse transcribed using 
the BioRad iScript reverse transcriptase and the reaction product diluted in 80pL 
of nanopure water. Forward primers, where possible from the published sequence 
(NM 019791), incorporated an endogenous methionine as a start site for 
translation, a Xho restriction enzyme site, a Kozak sequence and start codon. The 
reverse primer incorporated a Sal 1 restriction site (to facilitate subsequent 
cloning) after the removal of the termination codon, which would generate a 
fusion protein with eGFP in the pEGFP-N3 vector (Clontech). PCR reactions 
were performed with the Taq DNA polymerase using 3.5mM MgC12, (Promega) 
0.2pM of each primer, 0.2pM each nucleotide and lp1 of the diluted cDNA. 
Primer sequence, extension times and melting temperatures are included in Table 
1 and cloning strategy in Figure 6. Amplification products were run out on a 1% 
agarose gel stained with lOOpg/ml ethidium bromide and excised from the gel 
(PCR products are shown in Figure 7a). Each respective NRAGE fragment was 
Table 1: Primers generated to clone NRAGE fragments and for diagnostics. 
Melting temperatures of primers T,, Annealing temperatures and extension times for PCR 
reactions and nucleotide and protein predicted sizes are included. 
Name 
F 1 
F2 
F3 
F4 
F6 
F7 
Sequence 
GAG ACG CTC GAG ATG GCT CAG 
AAA CCG 
AGT GCC CTC GAG ATG CCA AAC 
AAC CAG 
GTG ACC CTC GAG ATG GAC CCA 
CCT GGA GCA 
TGG CCA CTC GAG ATG GCC TGG 
CAG AGT ACA 
GAC TGG CTC GAG ATG GGA CCC 
TCA CCT AAT CTG 
AAG CGC CTC GAG ATG GTG AGG 
GAT ATC ATC 
T, 
("C) 
64 
64 
69 
69 
66 
64 
Annealing 
Temp 
with R2 
("c) 
55 
55 
55 
55 
55 
55 
Extension 
Time 
2.5 min 
2 min 
2 min 
1.5 min 
1.5 min 
1 min 
Fragment 
size with 
R2 bp (kDa 
incl.GFP) 
2328 (1 16) 
1810 (96) 
1486 (84) 
1220 (74) 
1010 (66) 
845 (59) 

(F1)MAQKPDGGAGLRGFQAEASVEDSALLVQTLMEAIQISEA 
PPTSQATAAASGPNASPQSSQPPTANEKADTEVSAAAARPKTG 
FKAQNATTKGPNDYSQARNAKEMPKNQSKAAFKSQNGTPKGPH 
AASDFSQAAPTGKSAKKSEMAFKGQNSTKAGPGTTYNFPQSPS 
(F2)ANEMTNNQPKTAKAWNDTTKVPGADAQTQNVNQAKMADV 
GTSAGISEADGAAAQTSADGSQTQNVESRTIIRGKRTRKVNNL 
NVEENNSGDQRRASLASGNWRSAPVPVTTQQ(F3)NPPGAPPN 
VVWQTPLAWQNPSGWQNQTARQTPPAARQSPPARQTPSAWQNP 
VAWQNPVIWPNPVIWQNPVIWPNPIVWPGPIVWPNPM(F4)AW 
QSTPGWQSPPSWQAPPSWQSPQDWQGPPDWQVPPDWS(F5)MP 
PDWSFPSDWPFPPDWIPADWPIPPDWQNL(F6)RPSPNLRSSS 
NSRASQNQGPPQPRDVALLQERANKLVKYLMLKDYTKVPIKRS 
E(F7)MLRDIIREYTDVYPEIIERACFVLEKKFGIQLKEIDKE 
EHLYILISTPESLAGILGTTKDTPKLGLLLVILGIIF(F8)MN 
GNRATEAVLWEALRKMGLRPGVRHPLLGDLRKLLTYEFVKQKY 
LDYRRVPNSNPPEYEFLWGLRSYHETSKMKVLRFIAEVQKRDP 
RDWTAQFMEAADEALDALDAAAAEAEARAEARNR ( R1) M ( F 9 1 
GIGDEAVSGPWSWDDIEFELLTWDEEGDFGDPWSRIPFTFWAR 
YHQNARSRFPQAFTGPIIGPSGTATANFAANFGAIGFFWVE(R 

Construct in pEGFP-N3 
.? 
cloned into the pCR-BluntII-TOP0 vector using the TOPO isomerase ligation 
reaction, chemically transformed into Top10 supercompetent cells (as per 
manufacturer's instructions; Invitrogen) and plated onto LB-agar plates 
supplemented with 50pglml kanamycin. Random clones were grown overnight in 
LB media supplemented with kanamycin and plasmid extracted using the 
Eppendorf fast plasmid mini prep kit. 2pg of plasmid were digested with Xhol 
for validation and orientation of insert and grown in 125ml cultures for midi 
plasmid preps. Glycerol stocks were stored for future use. Nested PCR was also 
performed using the F(x+l) primer and Rl  to determine whether the product 
inserted was able to be amplified using internal primer sites. 
As there is a Xho site adjacent to the TOPO PCR product insertion site, 
we instead elected to use the Sacl restriction enzyme which cut upstream of the 
PCR insertion site. 1Opg of the NRAGE FxR2-TOP0 vectors and pEGFP-N3 
were digested sequentially with Sacl then Sall, as recommended by New 
England Biolabs. Reaction fragments were isolated in a 1% agarose gel stained 
with 100pgIml ethidium bromide and DNA excised from gel fragments by the 
QIAquick gel extraction kit (Qiagen - as per manufacturer's instructions). 
Ligation of the digested NRAGE fragments into the pEGFP vector was performed 
in 15pl reactions with lpl of T4 DNA ligase (NEB) overnight at 14°C then 
electroporated into TOP10 electrocompetent bacteria and plated on LB-agar 
plates with 50pglml kanamycin. Random colonies were picked, plasmid isolated, 
and digested with Sac1 and SalI to determine correct integration. Representative 
constructs (Fl,  F2, F3, F4, F9lR2-GFP) were sequenced to determine proper 
integration into the GFP vector and the framing of the NRAGE fragment into 
eGFP, using the pEGFP diag F primer to sequence into the multiple cloning site 
and the NRAGE F9 primer to sequence out of the NRAGE fragment and into the 
GFP vector. 
Cell Culturing and Transfections 
Human cell lines HEK 293 and N2A were maintained in DMEM 
(GibcoBRL) supplemented with fetal bovine serum (10% final concentration; 
Hyclone) and lx  antibiotic/antimycotic (100x stock solution; GibcoBRL). 
Murine P19 cells were grown in aMEM, supplemented with calf serum (7.5% 
final concentration), fetal bovine serum (2.5% final concentration) and 
79 antibiotic/antimycotic according to Jones-Villeneuve et al. . All cells were 
grown at 37°C at 5% C02. P19 cells were fed every day and passaged at a 1:10 
ratio every other day. 293 cells were fed every other day and passaged 1: 10 every 
third or fourth day. 
Transfections were performed in 6 well dishes at 70-80% confluency. In 
individual tubes, 8yg of DNA and lop1 of Lipofectamine 2000@ (Invitrogen) 
were diluted in 250yl of serum free DMEM each for 5 minutes then the DNA 
added to the Lipofectamine mixtures and incubated to allow the DNA:liposome 
complexes to form. Cells were washed with serum free media then the 
transfection mixture added with 1.5 ml serum free media. Cells were incubated 
for 4-6 hours at 37°C before the removal of transfection mixture and the addition 
of serum-containing media. Expression was assayed 24 hours post transfection 
using a Leica epifluorescence microscope at 50x magnification. Controls 
included the native pEGFP-N3 construct and mock transfections to assess 
efficiency. Efficiency was evaluated by estimating the number of fluorescent 
cells per field in comparison to the pEGFP-N3 transfections. 
For P19 cell transfections, a confluent plate of cells were passaged 1: 10 on 
day 1, transfection mixture was added as described above on the morning of day 2 
and six hours later an equal volume of media containing twice the concentration 
of serum was added, without removing the transfection mixture. 24 hours later 
(48 hours post split) cells were washed and standard PI9 media added and 
fluorescence analyzed by fluorescence microscopy before analysis by flow 
cytometry where appropriate. Transfection efficiencies were in the range of 30- 
60% with the longest NRAGE constructs giving consistently lower efficiencies, 
while expression intensity of the plasmids remained consistent across all 
constructs. 
Cell Lvsates and Western Blotting Procedure 
Cells were aspirated free of media, washed with ice cold PBS, and 
mechanically detached from the plates. Cells were collected and spun at 15OOrpm 
for 3 minutes before removing PBS and addition of 500pl RIPA buffer (150mM 
NaCl, lOrnM Tris, pH 7.2, 0.1% SDS, 1% deoxycholate, 5mM EDTA) 
supplemented with lpm sodium orthovanadate, lpm sodium flouride and protease 
inhibitor cocktail (Sigma: 104mM AEBSF, 80pM aprotinin, 2mM leupeptin, 
4mM bestatin, 1.5mM pepstatin A, 1.4mM E-64). Lysates were incubated on ice 
for 20 minutes before relative concentrations determined using the BCA protein 
assay kit using a round bottom 96-well dish according to manufacturer's 
instructions (Promega). The lowest mean protein concentration sample was used 
for the largest volume with the equal amount calculated for subsequent samples. 
For a 12 well comb, lOOpl was loaded (not including 2x loading buffer), a 15 well 
comb, 75p1 of lysate and for a 20 well comb, 50p1 of lysate. 
Protein samples were run on a 10% acrylamide gel overnight at 50 volts 
and the gel transferred to nitrocellulose membrane (Amersham Biosciences). The 
transfer was performed in a glycine-based submersion buffer for 2 hours at 0.5A 
at 4°C. The transfer membrane was washed in TBS 1% Tween (TBST) then 
blocked in TBST with 5% BSA (BSA+TBST) (for phospho-specific detection) or 
non-fat dry milk for 1-2 hours. Antibodies were added at appropriate 
concentrations (see Table 2) in milk or BSA+TBST overnight at 4°C. Membranes 
were washed in TBST three times for 15 minutes each prior to the incubation of 
the appropriate HRP-conjugated secondary antibody at a 1:10,000 dilution 
(BioRad) and strep-tactin conjugated HRP at a 1:5000 dilution (for the Precision 
Plus Molecular Ladder, when appropriate) for 45 minutes at room temperature. 
The membrane was subsequently washed by at least three 15 minute incubations 
and drained of fluid. Equal parts of the enhanced chemiluminescent (ECL) 
substrate solutions were mixed and washed over the membrane for 1 minute then 
the membrane dried to remove puddles and developed using Sensitive Blue X-ray 
film (Pegasus Scientific) and the in-house X-ray developer. Molecular rulers 
were either the Precision Plus blue stained ladder or the broad range ladder (both 
BioRad). NRAGE deletion constructs were immunoblotted for the GFP tag as the 
epitope for the commercially available NRAGE antibodies were removed in 
generating the constructs. 
Table 2: Antibodies: their source, dilution and application. 
Legend: WB: Western blot, FC: flow cytometry 
Antibody, clone 
number 
GFP 
P38 
p-p38 
Activated 
Caspase, Asp 175 
(5A1) 
Annexin V-PE 
(36) 
7AAD 
Actin 
Flow Cytometry Analysis of Apoptosis 
Three independent transfections were analyzed by Annexin V and 7AAD 
staining to determine the rate of apoptosis. At 48 hours post-transfection, cells 
were trypsinized to detach from the plate and spun at 1200 rpm for 3 minutes to 
pellet. lop1 of suspension was taken and cells counted using a hemocytometer to 
determine the number of cells per ml. Cells were diluted to 1 million per ml in 
Antibody Binding Buffer (0.1M HepesINaOH pH 7.4, 1.4M NaC1, 25mM CaC12 
diluted 1:10 in sterile water) included in the apoptosis detection kit (BD 
Biosciences). For controls, lOOpl of cells were placed in 5ml culture tubes with 
5pl of either Annexin V-PE or 7AAD or both and incubated in the dark for at 
Company, 
catalog number 
Santa Cruz 
Cell Signaling 
9212 
Cell Signaling 
921 1 
Cell Signaling 
9964 
BD Biosciences 
5 1-65875 
BD Biosciences 
51 -68981 
Sigma, A2228 
Dilution 
1:  1000 
1: 1000 
I: I000 
I: I000 
1 : 100 
1 : 100 
1 : 1000 
Species 
Rabbit 
Rabbit 
Rabbit 
Rabbit 
Preconjugated 
Preconjugated 
Mouse 
Application 
WB 
WB 
WB 
WB 
FC 
FC 
WB 
least 20 minutes (see Table 2). 250p1 of sample cells were incubated with 15p1 of 
each apoptosis marker for at least 20 minutes in the dark. Upon completion of the 
incubation period, cells were diluted in 400p1 (control) or 750p1 (sample) of 
binding buffer and analyzed by flow cytometry using the Becton Dickinson FASC 
Calibur flow cytometer and Cell Quest software version 3.3. GFP+ cells were 
gated and cell incorporation of Annexin V and 7AAD determined in a sample size 
of 5000 cells. Gates were determined using untransfected and unstained cells. 
GFP and PE were excited by the Argon 488 laser and GFP read on the FL1 
channel and PE on the FL2 channel. Compensation was set at 25.8% of the FL1 
channel to reduce bleed-through of the GFP signal into the PE channel. All data 
was plotted in the log mode. Statistics were performed using Microsoft Excel 
Data Analysis Software. ANOVA was performed to determine the statistical 
validity of the series of constructs and two tailed t-test performed for the 
statistically significant pairings. 
Chapter 3 
RESULTS 
The structure of NRAGE and the dissection of the protein 
The domains of NRAGE were identified in the protein sequence and 
whenever possible native methoniones were used as start codons for the construct. 
Nine constructs were designed to be generated with two reverse primers. The 
forward primers (Fl-F9) were designed upstream to the start of the region of 
interest while the R1 primer was designed to begin amplification at the end of the 
MAGE homology domain (MHD) and R2 to the end of the protein coding 
sequence. Fragments F1-F9lR2 were first cloned with constructs Fl-F4lR2 and 
F6-F91R2 successfully generated. F8R1 was also cloned for subsequent use. 
FIR2 encodes the complete NRAGE coding sequence while F2R2 takes off the N 
terminal sequence until the beginning of the NIHD2. F3R2 encodes a protein 
which begins after the MHD2 region ends. F4R2 and F5R2 each remove sections 
of the WQXPXX domain while F6R2 removes almost the entire WQXPXX 
domain. F7R2 and F8R2 delete regions of the MAGE homology domain while 
F9R2 only encodes for the extreme C-terminal end of the protein with no 
identified regions. F8R1 encodes for the second half of the MHD (schematic 
diagrams in figure 6, PCR products in 7a and Western blot in figure 7b). 
Cloning Strategy of NRAGE Constructs 
The forward primers were designed with a Xhol restriction digest site 5' 
to a designed Kozak sequence and start codon. Reverse primers deleted the stop 
codon and added a Sall restriction digest site which was all in frame to the 
pEGFP-N3 vector (Clontech). PCR products were generated from cDNA derived 
from adult mouse brain RNA. Products amplified matched predicted sequence 
sizes and were cloned into the TOPO cloning vector as per manufacturer's 
instructions. As the TOPO vector was not in the original cloning strategy it was 
subsequently discovered that there is a Xhol site near the 3' PCR product 
insertion site so digestion of the constructs with Xhol proved problematic. 
However, digestion with Xhol allowed us to determine in which orientation the 
PCR product was inserted into the vector as the products were either the predicted 
fragment size or essentially linearized. Therefore, Xhol was used as a diagnostic 
digest to 1) determine if the PCR product was in the vector and 2) which 
orientation the fragment inserted. Plasmids were digested and ligated into 
pEGFP-N3 and colonies digested to ensure correct fragment size. Representative 
constructs were also sequenced to ensure correct sequence. Constructs were 
transfected into 293 and N2A cells and showed expression by GFP and upon lysis 
and Western blotting, displayed immunoreactive protein at the predicted protein 
sizes (for fragment + GFP sizes, see table 2; Western blot, figure 8). 
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Figure 8: NRAGE Fragments are expressed in N2A and HEK293 Cells. N2A 
neuroblastoma cells and HEK293 cells were transfected with the NRAGE constructs and 
lysed after 24 hours. Shown are equivalent amounts of protein loaded on a 10% acrylamide 
SDS-PAGE gel electrophoresis and transferred onto a nitrocellulose membrane. The 
membrane was blotted with an anti-GFP antibody and developed using X-ray film. FIR2 
did not transfer. Molecular weight standards are on the Y-Axis. 
Description of the PI9 Cell Model System 
P19 cells were used as the model system of this study for two main 
reasons. P19 cells are a murine embryonal carcinoma cell line isolated by 
McBurney and colleagues 79 that can produce a multitude of cell types under 
various differentiation conditions. Importantly, when cultured in suspension 
supplemented with ~ o - ~ M  retinoic acid for four days then grown on tissue culture 
treated plates, they can produce neurons within 4 days of plating, and smooth 
muscle cells and oligodendrocytes within another 4 days. Furthermore, these 
cells have also been shown to differentially express neurotrophins and have been 
used as a model system to study neurotrophin responsiveness in neural 
development Because of these properties, P19 cells have become an accepted 
cell line to study the development of the nervous system and more specifically the 
molecular regulation of neurogenesis. P19 cells were transfected with 0.4pg 
DNA and lpl Lipofectamine 2000 per cm surface area of plate over a 24 hour 
period and transfection efficiency was determined by fluorescence of the GFP tag 
through fluorescence microscopy and Western blotting. 
NKAGE Constructs Cause Differential Apoptosis 
One goal was to identify the region of NRAGE responsible for the 
apoptotic events during neurogenesis. Deletion constructs generated above 
isolated the recognized domains of the protein as well as fragmented the regions 
in an effort to determine a minimal region necessary for apoptosis. Previous data 
in P19 cells show that full length NRAGE can induce apoptosis within 24 hours 
and reproducibly at 48 hours 22. Addition of BMP can accelerate this timeline to 
reproducibly at 24 hours, however we elected to wait the 48 hours to assay for 
apoptosis in order to demonstrate the true behaviour of NRAGE without 
supplementing with BMP. Thus, 48 hours after transfection, cell death was 
determined by Annexin V and 7AAD uptake by flow cytometry. Staining of three 
independent transfections showed a precipitous decrease in apoptotic cells 
transfected with Fragment 7, the fragment that does not contain any of the 
tryptophan-repeat region and part of the MHD (figure 9) and subsequent 
constructs F8R2 and F9R2 (ANOVA p=5.2 x 10.'~). 
Apoptosis by Annexin V 
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Figure 9: NRAGE constructs show differential apoptotic activity. Statistical analysis of the 
apoptotic potential of the NRAGE constructs in P19 cells. At three separate occasions, P19 cells 
were transfected with the NRAGE constructs, and 48 hours after transfection, were live stained 
with Annexin V-PE and analyzed by flow cytometry. Cells were gated for GFP+ cells and the 
presence of Annexin V-PE was read above a threshold determined by controls (single stained 
and unstained cells of GFP+ and untransfected cells). Statistical p-values are shown for the 
statistically significant construct pairings (further discussed in materials and methods and 
results). 
There is, however, a significant increase (p=0.01) in cell viability upon the 
expression of F6R2 signifying that the end of the WQXPXX region and the 
beginning of the MHD does contain some apoptotic response. However, levels of 
cellular apoptosis returns to control levels with removal of the entire repeat region 
and some of the MHD as in construct F7R2 (F6R2-F7R2 p=0.0009; F4R2-F7R2 
p=0.007). 
NRAGE Deletions Show Altered Caspase and p38 Activation 
Caspase 3 is a member of the executioner subfamily of caspases and as 
such is a broad-spectrum indicator of apoptosis. NRAGE has been shown to be 
involved in caspase-mediated activation and specifically caspase 3 cleavage, thus 
Western blot analysis was used to determine which fragments of NRAGE can 
mediate caspase activation. P19 cells transfected with the NRAGE constructs 
were lysed in RIPA buffer and subjected to Western blotting and 
immunodetection with an activated caspase 3 specific antibody. Presence of 
cleaved caspase 3 was detected in cells over expressing F1R2 and F2R2 
constructs. Caspase activation remained constant but decreased by about half 
with constructs F3, F4, F6 and F7R2 while no activated caspase was detected with 
F8R2, F9R2, and F8R1 signifying that these constructs can not mediate caspase 
activation (figure 10a). This is in partial agreement with the Annexin V staining 
described above, crediting constructs F l  through F6 with the initiation of 
apoptosis. However, this is in opposition to flow cytometry data, as these data 
show that F7R2 can initiate caspase cleavage however no appreciable level of 
apoptosis is seen by Annexin V. 
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Figure 10: NRAGE deletion show altered caspase and p38 activitv. A: PI 9 cells were 
transfected with the NRAGE constructs and lysed at 48 hours after transfection. Equal 
amounts of lysates were run on a 10% SDS-PAGE gel and immunoblotted to nitrocellulose 
membrane. Shown is an immunoblot analysis of cleaved caspase 3 from P19 cells. No 
cleaved caspase 2 could be deteced from F8R2 through pEGFP signifying a loss of caspase 
activity associated with apoptosis. Separate aliquots of cell lysates from the preparation 
described in figure 10A were simultaneously electrophoresed an immunoblotted with anti-p38 
antibodies. Upper panel shows phospho-p38 staining with signal diminishing to control levels 
at F8R2 while total p38 (lower panel) remained consistent. Presented here is the best of two 
attempts, the left side of the membrane did not transfer efficiently. 
The phosphorylation of p38 is a significant event in the NRAGE mediated 
apoptosis pathway and has been shown to be activated in both the presence and 
absence of BMP. P19 cells were transfected with the NRAGE-GFP constructs 
and lysed for SDS-PAGE analysis. Through the use of phosphate specific 
antibodies, it was found that p38 is phosphorylated in constructs F1-F7 while 
constructs F8R2, F9R2 and F8R1 show similar levels of phosphorylation to GFP 
control and in comparison to total p38. This signifies that the WQXPXX and the 
second half of the MHD are capable of downstream p38 activation, however the 
second half of the MHD is not sufficient to induce phosphorylation, as the F8R1 
construct which encodes the C terminal portion of the MHD can not induce 
phosphorlyation on its own (figure lob). 
NRAGE Constructs Show Differential Sub-Cellular Localization 
It is well documented that upon cleavage, MAGE protein localization can 
be altered, as the type I MAGE protein's MHD is transported to the cell surface to 
be the antigen of the major histocompatibility complex (MHC) '! A structure- 
function analysis of Necdin also showed subcellular localization differences in 
gene fragments not encoding regions of the MHD ' I .  To further investigate 
whether our NRAGE fragments showed differences in subcellular localization, we 
transfected the GFP-tagged constructs into various cell types to discern 
differences in sub-cellular localization. Upon inspection of the fluorescent activity 
of the NRAGE-GFP constructs, it was found that the constructs displayed a wide 
variety of subcellular localization patterns that were consistent across cell types 
[HEK 293 cells, N2A cells, P19 cells, as well as mIMCD3 cells, a mouse kidney 
epithelial cell line (personal communication, G. Nikopoulos)]. Figure 11 shows 
the subcellular localizations of the fragments in PI9 cells which were consistently 
bright at 12 hours but the largest constructs decreasing fluorescent activity 
significantly at 24 hours. Constructs FlR2, F2R2 show diffuse staining in the 
cytoplasm while being excluded from the region of the nucleus. Constructs F3R2 
through F8R2 and F8R1 show some cytoplasmic fluorescence but large focal 
points of fluorescence are observed in cytoplasmic regions, consistent with being 
in a subcellular structure such an aggresome or apopotosome. Fragment F9R2 
appears to be diffusely detected in the cytoplasm with no focal expression. This 
suggests that the WQXPXX region and the MHD, the regions involved in protein- 
protein interactions permit intracellular aggregation while the MHD2 regions and 
the extreme N and C terminal portions oppose these abilities. Interestingly, no 
construct seemed to localize to the membrane, which is significant as the type I 
MAGEs are proteolytically processed and presented on the cell surface and 
NRAGE is known to interact with several membrane bound proteins (p75NTR, 
UNC5H1, BMPR). This suggests that cell stimulation by appropriate ligands may 
be required for membrane and/or receptor localization. 


Chapter 4 
DISCUSSION 
This project was undertaken to give identity and function to the 
identifiable regions of the NRAGE protein. NRAGE is a member of the MAGE 
family of proteins, and as such has one highly conserved MAGE Homology 
Domain (NIHD), one less-well conserved domain, denoted MHD2 and a unique 
25 tandem WQXPXX tryptophan repeat region. The literature gives no definite 
function to the MHD of NRAGE however, several proteins have been shown to 
interact and have binding capacity to both the MHD and WQXPXX regions (see 
figure 3). It has also been demonstrated that repeat regions in general have 
possible binding capabilities. The trypotphan-rich region certainly has potential 
for binding as it is presumed to be 'sticky' and has a hypothetical binding-friendly 
confirmation. No NRAGE mutant mouse has been described (either transgenic or 
knockout) and previous cloning experiments have been restricted to the 
description of novel binding interactions. Moreover, it is only recently that 
NRAGE has been shown to interact with the non-canonical BMP-signaling 
pathway. Although NRAGE was originally cloned as a p75NTR intracellular 
domain interactor, the domain of NRAGE responsible for interactions with either 
p75NTR or the BMP receptors have not been characterized. Thus, an extensive 
cloning strategy was designed to isolate the various regions of NRAGE and an 
analysis of the apoptotic cascade in reference to the mutant constructs performed 
to isolate the region responsible for apoptosis and confirm its effects on 
downstream signaling cascades. 
The NRAGE MHD is Required for Apoptosis 
The published literature shows that of the known molecules that interact 
with NRAGE, one third have been show to interact with the WQXPXX domain, 
one third to interact with the MHD and the interactions of the remaining 
molecules have not been characterized. Thus our hypothesis was that the region 
that was responsible for apoptosis was either the MHD or the hexapeptide repeat 
region. The MHD is the region most conserved across all MAGE genes yet very 
few of the MAGE genes have been functionally characterized; NRAGE and 
Necdin are notable exceptions. Mutations in the paternal necdin locus (the 
maternal gene is silenced) are thought to be at least partially responsible for 
Prader-Willi syndrome, a developmental disorder that affects the brain. 
Molecularly, Necdin is highly expressed in post mitotic neurons and is thought to 
play a major role in preventing the neuron from re-entering the cell cycle. The 
MHD of the type I MAGE genes is the region that is presented within the major 
histocompatibility complex (MHC) of tumor cells to signal a cytotoxic T cell 
response and subsequent tumor rejection. However, the intracellular processing 
of the protein for presentation in the MHC has not been identified and as such, 
little is known about the protein. Yet even with these discoveries, the MHD7s 
function(s) has not been conclusively documented, nor trends been seen. This is 
the first evidence of a definitive role of the MAGE domain in any cellular 
function. 
The WQXPXX region was the other region that may have been involved 
in the apoptotic response. Repeat regions of proteins are important for protein- 
protein interactions and all MAGE-D genes have a repeat region, although there is 
no homology to one another. Proteins that have been shown to interact with this 
region of NRAGE have also been identified as downstream mediators of BMP 
signaling, thus it was reasonable to hypothesize that this region was required for 
downstream BMP mediated apoptosis. As all MAGE-D family members have a 
unique tandem repeat region, it may be that this region is important for 
interactions with partners rather than having a universal function shared among 
the MAGE-D family members. Although this region, through its binding 
interactions, could be requisite for NRAGE apoptotic functions, these 
experiments suggest that this is not the case. 
Western blotting data confirmed the flow cytometry data that the MHD is 
essential for apoptotic function however these results showed that the first half of 
the domain can also induce caspase and p38 activation. Although a significant 
decrease in apoptosis was seen by Annexin V staining at F6R2 (p=0.01) and 
essentially no apoptosis detected with constructs F7R2 through F9R2, this only 
reiterates the necessity for the MHD in cellular apoptosis. XIAP is a member of 
the non-canonical BMP signaling pathway and is a highly conserved apoptotic 
molecule. Where XIAP binds to NRAGE has not been identified. It can be 
surmised that NRAGE interacts with XIAP at the MHD as this region seems to be 
important in cell death. 
The result of the MHD being required in apoptosis was somewhat 
surprising for two reasons. First, the MAGE homology domain is the most well 
conserved and thus is most likely to have an evolutionarily essential function 
(such as inducement of apoptosis). So far, the other MAGE genes have not 
shown to be involved in apoptosis, it seems unlikely that this region would be 
implicated in yet another function. Apoptosis is a highly dynamic process with 
many proteins participating in a highly conserved cascade. If it is true that the 
MAGE-D genes are the most evolutionarily conserved, it would be surprising that 
these genes and especially the MHD would have diverged to perform another task 
from cell cycle withdrawal or MHC. Secondly, the suspected adhesive properties 
of the tryptophan repeat region was hypothesized to be important for the 
recruitment of co-apoptotic molecules. Indeed, molecules shown to be 
downstream of one of the major NRAGE- mediated apoptotic pathways interact 
with the repeat region. Although there is a decrease in apoptosis when the 
majority of the repeat region is lost, reduction of apoptosis to basal levels only 
occurs once a significant portion of the MHD as well as the entire WQXPXX 
region is deleted. This begs for speculation to what the MHD does to or interacts 
with to be so critical for programmed cell death. One yeast-two-hybrid screen has 
been performed with the MHD which isolated two proteins, one of which is 
important for NRAGE turnover however a second one using a neural 
development-specific library may uncover new interactors to the MHD 
specifically. Future studies currently underway will determine whether XIAP 
binding to NRAGE occurs at the tryptophan-repeat region or the MAGE 
homology domain, and where these interactions occur within the cell. 
NRAGE Fragments are Differentiallv Localized Within the Cell 
It was observed, upon inspection of GFP fluorescence, that the NRAGE 
fragments are differentially localized within the cell. This is consistent across cell 
types within the neural lineage (N2A, P19), across species (mouse P19, human 
N2A and HEK293) and across cell types (mIMCD3 epithelia, HEK293 
endothelia, N2A neuroepithelia). Full length NRAGE is consistently detected in 
the cytoplasm while mutant constructs generated in this study that express regions 
of the WQXPXX and MHD regions are detected peri-nuclear and in subcellular 
compartments. F9R2, the construct missing the entire MHD, does not give such a 
punctate staining pattern. A Necdin structure-function analysis showed similar 
variant expression patterns, with protein generally detected both in the cytoplasm 
and abundantly in the nucleus 81. Constructs missing portions of the MHD are not 
associated with the nucleus, rather are associated within the cytoplasm as 
speckles. Based on the observations of Taniura ", it could be hypothesized that 
the MHD is the region of NRAGE that confers the sub-cellular distribution, 
however due to the design of our constructs, the only fragment that does not 
contain the MHD is F9R2. 
The speckled appearance of certain NRAGE constructs raises questions as 
to why the protein is aggregated and with what it associates. The apoptosome is a 
conglomerate of APAF1, ATP, and caspase 9 and cytochrome c when released 
from the mitochondria. XIAP is associated with the apoptosome to prevent 
abberant pro-caspase 9 cleavage and NRAGE can interact with XIAP. Although 
the kinetics and biochemistry needs to be tested, it could be that these specific 
NRAGE fragments show differential binding to the components of the 
apoptosome and as such, can aggregate. However this aggregation may not be 
within the apoptosome but as part of an aggregate in general. It does not seem 
like the fragments aggregate through the WQXPXX region, as constructs missing 
this region still show a punctate staining pattern and the C terminal portion of the 
protein (and the GFP tag alone do not self-aggregate) so it may be assumed that 
the MHD is involved in the accumulation of the protein. This is in agreement 
with Taniura who also saw an aggregation of protein with constructs expressing 
the MHD. Little is known about the MHD, however further deconstruction of 
NRAGE by deleting the MHD while retaining the rest of the protein would 
confirm these results as well as further investigate the role of the MHD overall. 
MAGE genes are cytoplasmically processed in the golgi and the MHD is 
presented as the antigen of the MHC. There is no published literature of NRAGE, 
or any of the other MAGE-D family members being cleaved and presented as the 
MHC, however this is theoretically possible. Thus, the pattern of fluorescence 
aggregation may be a result of the MHD being sequestered into lysosomes for 
proteolytic processing. This pattern is observed in cells with constructs lacking 
the N terminal portion of the MHD2. No function has been described for the less 
well conserved MHD2, which is present in all MAGE-D proteins and some other 
type 2 MAGEs. It is possible that the NIHD2, or a portion thereof is responsible 
for preventing the proteolytic processing that would present the MHD on the cell 
surface. However, it is important to note that there was no detectable expression 
at the cell surface signifying that the MHC may not be functional in these cells or 
that the proteolytic process was not completed, due to a lack of proteins involved 
or the functionality of NRAGE itself. These experiments were done with the use 
of an epifluorescence microscope, confocal microscopy should be used to confirm 
these results as well as more accurately determine if the proteins are aggregating 
at an organelle. 
The C-terminal MHD is Essential for Caspase and p38 Signaling 
Western blot analysis of the NRAGE constructs yielded surprising results 
when compared to the Annexin V flow cytometry data. As discussed above, 
Annexin V staining, corroborated by 7AAD staining (not shown) indicates that 
there is a precipitous decrease of apoptosis with the F6R2 construct which deletes 
the WQXPXX region but over-expression of the F7R2 construct, which deletes 
the first half of the MHD, restores cell survival. However, both caspase and p38 
activation can occur in the absence of the N-terminal half of the MHD but only 
when the construct contains the extreme terminus of the protein. There are 
several reasons why these seemingly incompatible data can be explained. First, 
there may be an as of yet another unknown signaling pathway cooperating with 
the NRAGE-caspase 3 pathway to mediate the apoptosis cascade. In the absence 
of the first half of the MHD, caspase 3 can be activated, possibly through a p38 
mediated response however apoptosis as measured by Annexin V is not apparent. 
This second signaling pathway may interact with the N-terminal portion of the 
MHD, thus when removed with F7R2, it can not interact to perform its function. 
Indeed, this may be the region to which XIAP interacts, however future 
experiments are being designed to address this. Second, data also shows that the 
caspase 3 and p38 activation response only occurs when the C-terminal portion of 
the MHD and its subsequent unconserved region remain intact. Although the 
Annexin V experiments did not include the F8RI construct, it can be 
hypothesized that, based on Western blot data, the F8Rl construct would show no 
increase in apoptosis. This could be due to a conformational change in the 
folding of the MHD of F8R1, thus rendering it useless. However, this could also 
be due to incomplete binding of a protein which requires another protein to 
properly interact with NRAGE. NRAGE is widely accepted as an adaptor 
molecule for the various signaling pathway in which it interacts, this adaptor 
function may be as an accessory for docking. However, as stated above, 
significant further study needs to be completed to adequately explain why p38 and 
caspase activation does not structurally correlate with functional apoptosis assays. 
NRAGE has been described as an apoptotic molecule in both BMP and 
NGF mediated signaling. The experiments reported here were completed in the 
presence of serum, which likely has some level of BNIPs as well as neurotrophins. 
Considering the high levels of apoptosis in these pro-survival growth conditions, 
it is unlikely that the supplementation of the media of either growth factor would 
dramatically alter the results presented here, other than to speed up the response. 
Thus the addition of neither BMP nor neurotrophins more accurately 
demonstrates the apoptotic potential of NRAGE. That being said, there is the 
possibility that the two cascades are inducing apoptosis through separate 
pathways. However, as the addition of BMP emphasizes the apoptotic response it 
is possible that under these culture conditions BMP treatment overrides the 
response to any other serum component. Serum free cultures that include the 
addition of individual growth factors may be done in the future to determine if 
and how the individual NRAGE protein domains initiate downstream cascades 
independently. 
The NRAGE MHD is Required for Downstream BMP Activity 
Although it has been well established that BMPs can evoke an apoptotic 
response, the role of NRAGE in this process has only recently been identified. 
BMP ligands and receptors have been shown to co-localize to areas of 
neuroepithelial apoptosis 23,25,57 . Studies have also shown in vitro that BMP 
signaling induces apoptosis in chick rhombomeres and neural explant cultures. 
Noggin, the BMP antagonist inhibits these responses and the over-expression of 
BMP receptors can have an effect on cell survival. However, until NRAGE was 
categorized as a downstream effector of BNIP-mediated apoptosis, the Msx family 
of proteins has been the leading suspects in apoptosis. The Msx family encode 
homedomain genes well characterized as transcription factors involved in tooth, 
bone and skull formation. The Msx subfamily is extremely well conserved and 
the three genes (Msxl, 2, 3) have 98% homology within the homeodomain 
region. In spite of this similarity, they show distinct functions in neural 
development, but can still compensate for one another in times of genetic crisis. 
Msx genes have been shown to be involved in BMP-induced apoptosis as over- 
expression of Msx2 in aggregated P19 cells in suspension results in marked 
75 apoptosis . BMP promotes a similar level of apoptosis, however the two 
treatments do not show additive effects, signifying that Msx2 and BMP work 
through the same mechanism rather than parallel pathways 75. 
NRAGE was identified as an interactor with Msx2 in a yeast two-hybrid 
screen, thus implicating NRAGE in the Msx2 apoptotic pathway. Although no 
studies have determined that NRAGE interacts with Msx2 in neural apoptosis, it 
may be an unlikely event as the over-expression of NRAGE induces massive 
apoptosis in P19 cells within 48 hours, regardless of the presence or absence of 
BMP. BMP accelerates apoptosis in NRAGE over-expressing P19 cells 22, but 
the effects of NRAGE-induced apoptosis is more rapid and context independent 
with respect to Msx2. The evidence that NRAGE and Msx2 interact is not in 
dispute, however it seems unlikely these two proteins work through a similar 
pathway to induce programmed cell death in neural development, especially as 
the region of NRAGE that Msx2 binds is not required for apoptosis (i.e. the 
WQXPXX repeat region). NRAGE-dependent apoptosis outside of the nervous 
system has not been well studied thus it is possible that the two proteins cooperate 
in a separate system (such as bonellimb development) to bring about a mutual 
response. 
To date, NRAGE best fits as a member of the non-canonical BMP 
signaling pathway. NRAGE has been shown to co-immunoprecipitate with 
XIAP, TAKl and TAB1 however none of these interactions have been localized 
on the NRAGE protein. XIAP has been shown to interact with both BMPRla and 
NRAGE through its RING-finger domain. Moreover, TAB1 can interact with 
XIAP via its BIR domain and TAKl can induce p38 phosphorylation in the 
presence of BMP stimulation. Western blotting shows that the first half of the 
MHD is required for p38 activation and this is likely a result of the loss of 
NRAGE association with XIAP. However, the region of NRAGE required to 
interact with XIAP has not yet been defined, although we may be able to 
hypothesize that the C-terminal portion of NRAGE is where XIAP binds, based 
on the apoptosis studies described above. Future studies are being designed to 
address these issues. 
The MHD of NRAGE is Likelv Responsible for its Function Within the 
Neurotrophic Theory 
NRAGE was first described as an interactor with p75NTR and as such may 
play an important role in the neurotrophic theory. Importantly, NRAGE was 
found not to bind with the death domain region of p75NTR (the region to which 
NADE associates and confers its apoptotic potential) but rather the 
13 juxtamembrane region . The neurotrophic theory is based on the premise that 
neurons which do not receive enough signal in the form of neurotrophins die due 
to the lack of survival cues. Although many interactors of p75NTR have been 
identified, there has been a lack of clarity as to the mechanism which p75NTR can 
confer the apoptotic signal. It has been described that p75NTR can induce 
apoptosis both with and without ligand activation. This is likely cell context 
dependent as other studies have showed that p75NTR can induce apoptosis under 
the direction of NGF in cell types such as differentiated rat oligodendrocytes, 
Schwann cells, hepatic stellate cells, MAH cells, and many others (reviewed in 
54 ). However, in vivo data show that apoptosis is reduced when mouse embryos 
are exposed to antibodies to NGF or the extracellular domain of p75NTR. There is 
also a hypomorphic knockout of the third exon of p75NTR which also shows 
reduced apoptosis 4s. Furthermore, transgenic over-expression of the intracellular 
domain of p75NTR show decreased cell number in the cortical, sympathetic and 
sensory neurons 4" Studies have also shown that co-expression of p75NTR with 
Trk receptors can augment the affinity of neurotrophins to their respective 
receptors. Recently, a ligand for p75NTR has been described and is ironically, the 
uncleaved form of NGF. Pro-NGF appears to be a high affinity ligand for p75NTR, 
can not bind with TrkA and can induce p75NTR mediated apoptosis in sympathetic 
neurons, oligodendrocytes and vascular smooth muscle cell lines 82,83. Sortollin is 
a co-receptor necessary for Pro-NGF to signal upon p75NTR. Overexpression of 
Sortollin in cells that do not normally express it renders these cells susceptible to 
the pro-apoptotic effects of pro-NGF on the p75NTR receptor It is possible, that 
in a severe shortage of neurotrophins (to act upon the heterodimeric receptor 
complexes), or in cells that do not display the Trk receptors, that p75NTR can 
receive the NGF signal on its own or through pro-NGF stimulation with Sortollin, 
either of which evoke the apoptotic response. 
NRAGE has not been shown to interact with any of the Trk receptors, nor 
Sortollin and over-expression of NRAGE can disrupt the binding of p75NTR to the 
Trk receptors. This competitive mechanism of p75NTR between Trk and NRAGE 
may be responsible for the apoptosis seen in the developing brain. As it has now 
been shown that the MHD is required for apoptosis in the developing brain, it 
seems likely that this region is responsible for interaction to the juxtamembrane 
region of p75NTR, although this has not been confirmed biochemically. 
Furthermore, studies are needed to address the role of Sortollin in the pro-NGF 
initiated apoptosis response and the role NRAGE has in this mechanism. It is 
conceivable that NRAGE may function with p75NTR both in the presence and 
absence of Sortollin to confer apoptosis, and the role of Sortollin in this system 
may be to evoke a temporal- or spatial-sensitive response. However, Sortollin 
and NRAGE may have little to do with each other and instead the presence of 
Sortollin at the p75NTR may somehow inhibit the p 7 5 N T R - ~ ~ ~ ~ ~  interaction. 
NRAGE's Possible Activity as an Axon Guidance Molecule 
UNC5H1 is a membrane-associated protein involved in axon guidance and 
apoptosis in the brain (reviewed in "1. UNC5Hl is the closest related family 
member to p75NTR and it has been shown that the PEST and Zu-5 regions of 
UNC5Hl are important to interact with the MHD and downstream parts of 
NRAGE. Both p75NTR and UNCSHI have been shown to be important in 
neuronal apoptosis and both have a PEST sequence. Although this region is 
primarily associated in the rapid turnover of proteins through degradation 
machinery, it is interesting to note that these regions in UNC5Hl are 
juxtamembrane, the same site where NRAGE interacts with p75NTR. Thus it is 
tempting to speculate that these two membrane receptors can mediate apoptosis 
through similar mechanisms and interactions with NRAGE. It is interesting to 
note that over-expression of UNC5Hl induced substantial apoptosis in native 
PC12 cells but not differentiated cells and the over-expression of NRAGE in 
differentiated PC 12 cells induced the cells to retract their processes. 
Neurotrophins, the ligands of p75NTR and the Trks, are also involved in process 
outgrowth. Neurotrophins induce process outgrowth of neural cells as method of 
innervating the target tissue from which the trophin is produced. Processes are 
essential to this process, perhaps low levels of neurotrophic stimulation encourage 
the cell to send out processes but there is an insufficient level of survival stimulus 
at the target to sustain all responding cells. Thus the insufficiency of neurotrophin 
ends in neurotrophin-mediated apoptosis. It is known that NRAGE is present in 
the cell that produces processes and is available to receive the stimulus to 
apoptose. It is tempting to speculate that NRAGE is involved (or at least present) 
in the search for the neurotrophin-secreting target and that the lack of survival 
factor upon reaching the target triggers NRAGE-mediated apoptosis. The exact 
stimulus response mechanism is not clear, but future studies may be designed to 
investigate the role of NRAGE in this mechanism. 
NRAGE's Involvement in Cancer 
NRAGE is a member of the MAGE family of genes which were originally 
identified as tumor antigens, however, the antigenic function has only been 
attributed to type I MAGE clusters A, B, and C. The MAGE protein is 
cytoplasmically processed and the MAGE domain is presented in association with 
the antigens of the major histocompatability complex in a variety of tumor cells 
including melanoma, breast and prostate 84. This presentation results in cytotoxic 
T cell response and subsequent tumor rejection. Although only expressed in a 
certain number of patients, this mechanism has been harnessed for therapeutic 
purposes, because when MAGE was experimentally over-expressed in cancer 
cells, there was regression when tumor-bearing mice were immunized with 
hMAGE-A3 8"x8 . In a clinical study, HLA-A1 patients who expressed MAGE-3 
(previous nomenclature) on their tumors were administered MAGE-3 
immunization, one quarter of these patients showed a regression of the metastases 
however there was no cytotoxic T cell response detected 84. Currently, there are 
more than 6 clinical trials testing the efficacy of various MAGE gene treatments 
primarily in multiple melanoma and using MAGE-A genes 89. 
BRCA2 
Germline mutations in BRCA2 are responsible for predisposing women to 
breast and ovarian cancers, and rarely, sporadic mutations are found in breast 
tumors. BRCA2 also has many cellular responsibilities in normal biology 
including the stabilization of stalled DNA replication forks, cytokinesis, 
gametogenesis, transcription regulation, suppression of cell proliferation and 
centrosome duplication (reviewed in 90). BRCA2 has also been shown to inhibit 
the proliferation of the pancreatic cancer line Capan-1 90. Using the conserved 
region of the gene, it was found that BRCA2 can associate with the 116 C- 
terminal amino acid residues of NRAGE with high affinity (figure 4), and 
BRCA2 can increase the half life of NRAGE protein six-fold in the presence of 
cyclohexamide 90. As many others have implicated NRAGE in the cell cycle, 
studies were conducted to determine the role of the BRCA2:NRAGE interaction. 
It was seen that both NRAGE and BRCA2 decrease the number of cells that 
incorporate BrdU, at a similar rate to p53, and this is an additive effect when both 
are transfected in combination 90. The effects of over-expression of NRAGE and 
BRCA2 are similar in a mammary tumor cell line void of p53, suggesting that 
repression of the cell cycle is through a pathway independent of p53. However, 
growth retardation by BRCA2 is dependent on NRAGE as loss of NRAGE 
through RNA inhibition (RNAi) restores the growth potential 90. The majority of 
breast tumor cell lines show low levels of NRAGE expression. However all the 
untransformed mammary epithelial cell lines and four of the more than twenty 
tumor lines show significant NRAGE expression. This signifies that NRAGE 
expression may be important in maintaining an normal state 90. 
Recently there have been two studies which show an association of 
NRAGE and cancer. However, the revelation that NRAGE is associated with 
cancer is not surprising since apoptotic cascades have long been associated with 
the disease as they are likely targets for mutations. NRAGE and BRCA2 together 
induce growth inhibition and some rare breast cancer cell lines (4 of more than 20 
studied) show a lack of NRAGE protein. Furthermore, in a separate study, it was 
seen in rare subset of well differentiated yet highly invasive breast tumors, there 
are disproportionately high levels of BMPRlb and XIAP 9' .  Although not 
directly studied or mentioned, it may be there is a loss of NRAGE activity 
associated with these two proteins, which can cooperatively associate to induce 
apoptosis. Although there is little data to back this up, normal BRCA2 may be 
able to extend the half life of NRAGE and thus repress the malignant growth of 
cells. Upon loss of or mutation of BRCA2, there is subsequent rapid degredation 
and loss of NRAGE protein which in turn leads to a decrease in apoptosis. This 
and over-expression of BMPRlb and XIAP could both contribute to breast cancer 
through similar or different mechanisms. There is much to study to confirm this, 
but if true, NRAGE could be involved in breast cancer progression. 
Chapter 5 
LIMITATIONS AND FUTURE STUDIES 
Limitations of the Presented Studv 
This study utilized a cloning strategy that drastically reduced the NRAGE 
protein in order to isolate the recognized regions. In light of the Necdin structure- 
function study, in which the authors deleted only the region of interest without 
interfering with the upstream or downstream regions of the protein, it would be 
appropriate to deconstruct NRAGE in a similar manner to compare these sibling 
proteins. Furthermore, a less drastic manipulation of the protein would also more 
accurately demonstrate the true function of the region by minimizing the 
conformational changes and the ancillary functions of the upstream regions. 
However, by employing the cloning strategy'outlined in this study, we may have 
discovered a function in the MHD2 region, as we have shown that the loss of the 
MHD2 changes the subcellular distribution only when the MHD is intact. 
Technical difficulties are abundant when studying a protein involved in 
apoptosis, as it is difficult to maintain a population of expressing cells. Apoptosis 
as measured by flow cytometry was evaluated at 48 hours, however data not 
presented here demonstrated that at 24 hours we did show a similar pattern of 
degree of cellular death. Thus, Western blot and sub-cellular expression analysis 
was performed at 24 hours as it was found that the protein was more abundantly 
expressed at this time point. However, it was still problematic to transfect the 
constructs, especially the longest ones and detect these proteins through western 
blot analysis. The longest fragment is ten times larger than the smallest fragment, 
thus transfection with equal weights revealed that the shorter fragments had 
consistently greater expression due to the number of plasmids integrated into the 
cell. However, pre-experimentation transfections revealed that altering the 
amount of plasmid transfected did not drastically alter the degree of expression in 
the cells. This is likely due in part to the optimization of the Lipofectamine 
transfection protocol, which 'maxes out' the plasmid:liposome ratio in the media. 
Altered sub-cellular localization was shown with the NRAGE mutant 
constructs through epifluorescence microscopy however, it can not be definitely 
concluded that there was no localization to the membrane. To validate these 
conclusions, confocal microscopy using P19 cells expressing the NRAGE 
constructs is required. Furthermore co-staining with markers specific for the 
apoptosome (APAF1 or caspase 9) or the golgilendoplasmic reticulum would 
further elucidate where in the cell these mutant proteins aggregate. 
Future Studies 
In order to fully characterize the structure-function analysis of NRAGE, 
the proliferation and differentiation aspects of NRAGE function need to be 
investigated. Previous reports have shown that NRAGE expression can influence 
the cell cycle through its actions on p53 activityz2. Overexpression of NRAGE 
attenuates BrdU incorporation which signifies an exit from the cell cycle. 
Therefore, BrdU incorporation assays, utilizing flow cytometry to read the 
percentage of GFP+ cells that incorporate BrdU, would identify changes in the 
cell cycle dynamics of cells expressing the NRAGE mutant constructs. It is 
expected that an intact MHD would abbreviate the cell cycle and induce a more 
rapid exit from the cell cycle, while the loss of the MHD would when the latter 
constructs are overexpressed would not alter the cell cycle kinetics. 
It has also been demonstrated that the loss of NRAGE can alter the 
differentiation potential of P19 cells, as there is a reduction in the production of 
neurons at a result of the cell failing to cease the progenitor genetic program. A 
thorough analysis of the NRAGE mutants described here, as well as the GFP 
control, transfected into PI9 cells then taken through the retinoic acid-mediated 
differentiation program would be warranted. At the termination of the program, 
cells would be stained for MAP2alb (a neural marker), GFAP (a glial marker) and 
Mash1 (a neural stem cell marker) to determine the percentages of the cells in the 
various developmental stages. As Kendall et al. ", showed that with a loss of 
NRAGE there is a gain of progenitors at the expense of neural populations (at 8 
days of differentiation), it would be expected that the loss of the MHD would 
show similar results (i.e. F7, F8, and F9R2) as there would be no functional 
NRAGE signal. However, the overexpression of the constructs with the MHD 
intact would induce a rapid cell cycle exit which would allow the cells to 
terminally differentiate more quickly which would be seen by an increase in glial- 
positive cells. 
We have demonstrated that the loss of portions of the NRAGE protein can 
alter the co-localization of the remaining protein to discrete regions of the cell 
upon over-expression. These results are consistent with the structure-function 
analysis of Necdin in which mutants that do not encode for the MHD or the N 
terminus are distributed uniformly in the cytoplasm. Although we have seen that 
some of the NRAGE mutants built may reside by or in the nucleus, in aggresomes 
or apoptosomes, confocal imaging with other markers is required to confirm 
nuclear localization or localization within aggregated structures. To elucidate 
whether the apoptosome is the where the construct concentrates, tagged molecules 
of the apoptosome such as a pro-caspase 9 or APAFl construct will help define 
whether this structure is the apoptosome. However, NRAGE may also co-localize 
with other known interactors, such as TAKl and TAB1, or p38 in the non- 
canonical BMP pathway, MsxIDlx, or Necdin. Necdin deletion mutants can 
subcellularly localize, thus these two proteins may work in a similar mechanism 
to elicit downstream responses and their mutants behave in an analogous fashion. 
Indeed, future studies employing both NRAGE and Necdin may shed significant 
light on the role of the MHD in functions other than MHC-mediated cytotoxic T 
cell response. 
XIAP is a known mediator of the non-canonical BMP signaling and also 
interacts with NRAGE. However, it not known with which region of NRAGE 
XIAP can interact, thus co-immunopreciptation of the NRAGE constructs with 
XIAP (as a XIAP-dsRed monomer construct or endogenously) will help to 
determine where XIAP interacts with NRAGE. Furthermore, it is still unknown 
where XIAP and NRAGE meet within the cell to confer the apoptotic signaling. 
In light of the interesting result of the NRAGE cellular localizations, confocal 
imagery of the two proteins (as GFP and dsRed constructs, or YFPICFP 
constructs which are currently being prepared) will help determine where in the 
cell the two proteins interact. These interaction studies may also shed light onto 
the interesting results seen in this study on the MHD. Several lines of evidence 
justify the hypothesis that XL4P interacts with the N-terminal half of the MHD. 
Caspase 3 and p38 activation occur in the absence of the N-terminal MHD 
whereas apoptosis is not apparent when the N-terminus of the MHD is intact. If 
XIAP does interact here, it stands to reason that XIAP inhibits NRAGE-mediated 
apoptosis even in the presence of caspase 3 activation. However, when binding of 
XIAP is lost, then the C-terminal portion of the MHD can signal apoptosis, as 
seen in the Annexin V data. 
NRAGE was first identified as molecule interacting with the 
juxtamemembrane region of p75NTR however, little has been found as to the 
downstream activities of NRAGE after p75NTR interaction. Future studies must 
address this issue. Published yeast-two-hybrid screens have only uncovered the 
E3 ubiquitinating protein Prajal as interacting with NRAGE. A second screen, 
focusing on the MHD may help elucidate downstream interactors of NRAGE 
under the control of p75NTR. Furthermore, 2-dimensional gel analysis of 
neuroblasts and neurotrophin-stimulated neuroblasts may help elucidate changes 
in protein expression that could be attributed to apoptosis. On the other hand, the 
discovery of Sortollin and pro-NGF as the ligand and co-receptor of p75NTR may 
also be of interest to future NRAGE-focused studies. As mentioned above, these 
molecules may play a role in the upstream mediated response of p75NTR and 
ultimately the fate of the cell itself. 
Surprisingly, none of the mutant NRAGE molecules built appeared to 
show a sub-cellular localization to the membrane compartments. This is 
surprising as NRAGE is known to interact with at three membrane-bound 
receptors (p75NTR, BMPR, UNC5Hl). Future studies using construct-bearing 
cells treated with either BMP or neurotrophins may show that certain constructs 
can move to the membrane-associated receptor upon appropriate stimulation. The 
NRAGE mutants were inserted into the pEGFP construct so as to detect its 
expression as all commercially available NRAGE antibodies have epitopes to the 
N-terminus. Antibodies generated to recognize the extreme C-terminus or the 
MHC of NRAGE would be useful to confirm these findings. 
As stated above, these studies were all performed in the presence of 
serum, however, the addition of ligands may influence the translocation of the 
molecule in the cell. These studies will also shed light onto the requirements of 
the receptor-mediated apoptotic signaling cascade on NRAGE. This would clarify 
NRAGE is itself responsible for the downstream be through its own interaction 
with NRAGE or the necessary downstream cascades that NRAGE interacts with 
to confer its apoptotic potential. These studies will help determine whether the 
deletion of a specific region prevents apoptosis at the membrane level or 
downstream of NRAGE. 
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